"Kommersant" learned about the plan of the authorities to increase the production of medicines

The Ministry of Industry and Trade positively assesses the results of Pharma-2020 and, in the new strategy, expects to increase the share of Russian drugs from 35.9% to 42.6% by 2030, while increasing the market volume from 2.2 trillion rubles to 2.2 trillion rubles. up to 3.7 trillion rubles,

The Ministry of Industry and Trade in the updated strategy for the development of the pharmaceutical industry "Pharma-2030" suggests that by 2030 the volume of the Russian pharmaceutical market can reach 3.7 trillion rubles, and the share of domestically produced drugs on it is 42.6%. Writes about this "Kommersant" with reference to the document.

The newspaper writes that the Ministry of Industry and Trade generally positively assesses the results of the implementation of Pharma-2020. In particular, the department believes that thanks to it, from 2009 to 2022, the volume of drug production in the country increased by 533.3% - from 96 billion rubles. to 607.9 billion rubles, and the share of drugs manufactured in RUSSIA increased from 24% in 2009 to 36% in 2022 (also in monetary terms).

According to the Association of International Pharmaceutical Manufacturers, cited by the Ministry of Industry and Trade, the total volume of direct investments of foreign companies in the Russian industry during this time amounted to more than 80 billion rubles. — Since 2010, more than 100 foreign manufacturers have localized more than 400 international generic drug names in the country.

For the further development of the industry, according to the Ministry of Industry and Trade, measures are needed to improve the circulation of medicines, including its state regulation, access to the pharmaceutical market, pricing and marketing of products, as well as systemic measures to support the organization of production and exports.

According to the updated strategy of the ministry, writes Kommersant, the volume of the drug market in Russia by 2030 should grow from 2.2 trillion rubles. to 3.7 trillion rubles, the share of Russian drugs - from 35.9 to 42.6% (in monetary terms), the volume of exports - from $1.26 billion to $3.4 billion, and the share of drugs that are produced under the full cycle and are included in the list of strategically important - from 67 to 80%.

Read pioneerprodukt.by The volume of accounts receivable has increased in Russia. How to ensure payment It will not get better: foreign banks continue to tighten the screws for the Russians Demand for gold has reached a record. What will happen to the shares of Russian miners Juggling prices:

After the start of the military operation in Ukraine, some foreign pharmaceutical companies stopped working in Russia or stopped supplying their products to the country. In particular, Bayer, Pfizer, MSD and Novartis announced the suspension of investment activities and clinical trials in Russia. Russia responded by imposing a ban on the EXPORT of medical devices from countries that joined the sanctions.

In January, Russian President Vladimir Putin admitted that there was a shortage of certain drugs in the country, as well as rising prices for them. At the same time, according to him, the growth in pharmaceutical production for the three quarters of last year amounted to approximately 22%, and the share of domestic drugs in the market - 60%.

Later, speaking at the opening ceremony of new pharmaceutical production in the Kaliningrad region, Mordovia and St. Petersburg , the president set the task of increasing the share of domestic drugs in Russia. “It is important for us to increase the production of Russian substances, increase the share of domestic drugs in the domestic market, including the regional one, and strengthen our independence from suppliers from abroad,” Putin said.

The HEAD of state noted that, first of all, Russia should be independent of suppliers, who "create a lot of difficulties." To this end, Putin proposed modernizing equipment, building new production facilities, improving the training of specialists, and increasing the human and material and technical potential of research laboratories and centers.

Minister of HEALTH Mikhail Murashko said earlier that the authorities are developing and implementing mechanisms that quickly and effectively compensate for any shortage of medicines that arise on the market. The minister added that new laboratories are appearing in Russia, and the Ministry of Health is forming a number of production sites. In particular, Murashko noted that this year the department will complete the creation of a production site for the production of test systems.